Posts

A biotech company focused on short-duration psychedelic-assisted therapies for mental health conditions announced positive top-line results from the first placebo-controlled efficacy study exploring a short-duration psychedelic for the treatment of major depressive disorder.

Psychedelic and psychedelic-assisted therapies in the neuropsychiatric space have stalled for decades.